ArticleStem cell research & therapy2026
Curcumin pretreatment enhances the capacity of BMSC exosomes to attenuate renal ischemia-reperfusion injury by ferroptosis suppression via miR-16-5p/Smad3/Mb axis.
Article in Stem cell research & therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Curcumin-preconditioned bone marrow mesenchymal stem cell exosomes ameliorate postmenopausal osteoporosis by activating mitophagy in osteoblast-lineage cells.Frontiers in cell and developmental biology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
backgroundRenal ischemia-reperfusion injury (RIRI) refers to kidney damage following blood flow restoration, with limited effective treatments available. Bone mesenchymal stem cell (BMSC) derived exosomes exhibit therapeutic potential via targeted molecular delivery, though limited by isolation challenges and transient retention, while curcumin demonstrates multi-organ protective capacities in RIRI.
methodsIn vivo, RIRI mice received tail vein injections of BMSC exosomes (exo) or curcumin preconditioned BMSC exosomes (cur-exo). Biodistribution was tracked via bioluminescence/immunofluorescence, while therapeutic efficacy was evaluated through renal function parameters, histopathology, and ferroptosis biomarkers. In vitro, ferroptosis-induced renal tubular epithelial cells were treated with exo and cur-exo, with subsequent quantification of Fe²⁺, lipid peroxidation, glutathione, mitochondrial ultrastructure, ROS levels, and ferroptosis-related protein/mRNA expression. Mechanistic studies integrated transcriptomics, siRNA/overexpression systems, ChIP, dual-luciferase assays, SPR, Co-IP and bioinformatics to delineate anti-ferroptosis pathways of cur-exo and the effect of curcumin on miR-16-5p.
resultsCurcumin preconditioning can enhance the targeted delivery capability of BMSC exosomes to injured kidneys and improves the restoration of renal function and tissue damage in mice with ischemia-reperfusion injury by inhibiting ferroptosis. In vitro, TCMK-1 cells can take up both exo and cur-exo, with cur-exo significantly enhancing the survival rate of TCMK-1 cells induced by ferroptosis compared to exo. This is achieved by downregulating lipid peroxidation levels, improving iron overload and ROS accumulation, and restoring mitochondrial structure to exert anti-ferroptosis effects. Mechanistically, curcumin increases the expression of miR-16-5p in cur-exo by regulating the activity of CYP1B1, and cur-exo inhibits the translation of Smad3 by delivering miR-16-5p that targets the 3'UTR of Smad3, leading to the downregulation of myoglobin (Mb) transcriptional activity and thereby antagonizing ferroptosis in TCMK-1 cells.
conclusionOur research indicates that curcumin preconditioned BMSC exosomes can exert a therapeutic effect on RIRI by inhibiting cellular ferroptosis. The primary mechanism behind this effect involves curcumin increasing the expression of miR-16-5p by modulating CYP1B1 activity, and cur-exo promoting the alleviation of ferroptosis in TCMK-1 cells through the miR-16-5p/Smad3/Mb axis. This study provides a new strategy for enhancing the biological functions of exosomes and presents new targets and ideas for the treatment of RIRI.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.